Ocella birth control pills may increase your risk of blood clots, pulmonary embolism, deep vein thrombosis (DVT), heart attack, stroke, and death. If you still need to file an Ocella lawsuit against Bayer HealthCare, contact Schmidt & Clark, LLP for comprehensive legal assistance.
What is Ocella?
The birth control pill Ocella is a generic version of Yasmin, and both medications contain a combination of drospirenone (progestin) and ethinyl estradiol (estrogen). Ocella is designed to prevent pregnancy by inhibiting ovulation, thickening cervical mucous, and thinning the lining of the uterus.
Safety Problems with Ocella Birth Control
The problem with Ocella is the ingredient drospirenone, a “fourth-generation” version of the female reproductive hormone progestin. Experts have known for decades that progestin increases the risk of blood clots — but some progestins have higher risks than others. Recent studies have linked drospirenone in Ocella to a tripled increased risk of blood clots compared to levonorgestrel, and it is no more effective at preventing pregnancy.
Bayer HealthCare, the manufacturer of Ocella and Yasmin, is facing over 11,000 lawsuits from women who took a drospirenone-containing contraceptive and developed blood clots or gallbladder disease. By the end of 2013, over 7,000 claims involving venous blood clots settled for $1.4 billion, for an average payout of $200,000 per plaintiff. In addition, $24 million has been set aside to settle lawsuits involving gallstones and surgery to remove the gallbladder (cholecystectomy).
Ocella and Generic Drug Lawsuits
Recently, the Supreme Court ruled that manufacturers of generic drugs are not liable for failing to disclose side effects of their medications — effectively protecting the financial interests of pharmaceutical giants instead of injured people like yourself. If you had a blood clot after taking Ocella (generic Yasmin), you may have been told that you won’t be able to file an Ocella lawsuit against Bayer.
Fortunately for you, the Supreme Court ruling may not apply — Bayer HealthCare, the manufacturer of Yasmin, supplied generic drug companies with the controversial ingredient in Ocella, drospirenone. This means they could still be held financially liable for failing to warn about the risks of drospirenone.
FDA Safety Warnings for Ocella
In September 2011, the U.S. Food and Drug Administration (FDA) published a Safety Communication to warn about the risk of blood clots from Ocella. They were concerned because an FDA-funded study involving 800,000 women linked drospirenone to a 50% increased risk of blood clots.
Blood clots from Ocella are an extremely serious, emergency medical condition. They usually form deep inside veins in the lower legs or thigh, in a condition called deep vein thrombosis (DVT). Without treatment, blood clots can grow very large and cause severe circulatory problems in the limbs.
Ocella blood clots can also travel throughout the body and get trapped in vital organs, cutting off circulation. One of the most common complications of DVT is a pulmonary embolism, in which blood clots get trapped in the lungs and cut off circulation of blood. This can rapidly cause severe pain, organ damage, and even death.
Ocella Risks & Complications
- Blood clots
- Venous thromboembolism
- Heart attack
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Gallbladder disease
- Organ damage (blindness, brain damage, etc.)
- And more